Description: Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Home Page: atrinpharma.com
APRE Technical Analysis
535 Boylston St.
Boston,
MA
02116
United States
Phone:
617-463-9385
Officers
| Name | Title |
|---|---|
| Mr. Christian S. Schade | Chairman & CEO |
| Dr. Oren Gilad Ph.D. | Co-Founder, Pres & Director |
| Mr. Scott M. Coiante | Sr. VP, CFO & Sec. |
| Dr. Gregory A. Korbel Ph.D. | Sr. VP & COO |
| Dr. Dansu Li Ph.D. | Head of Technology |
| Dr. Lars B. Abrahmsen Ph.D. | Sr. VP & Chief Scientific Officer |
| Dr. Rifat Pamukcu M.D. | Chief Medical Advisor & Director |
| Mr. Hank Breslin | Head of Medicinal Chemistry |
| Dr. Michel Afargan Ph.D. | Head of Pharmacology Devel. |
| Ms. Andrea Epstein | Controller |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0351 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-10-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |